Coronary calcium scoring for guiding lipid-lowering therapy is cost-effective: time to remove barriers to its use

Medical Journal of AustraliaVolume 218, Issue 5 p. 214-215 Editorial Coronary calcium scoring for guiding lipid-lowering therapy is cost-effective: time to remove barriers to its use Erfan Tasdighi, Erfan Tasdighi Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, United States of AmericaSearch for more papers by this authorMichael J Blaha, Corresponding Author Michael J Blaha [email protected] Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, United States of America[email protected]Search for more papers by this author Erfan Tasdighi, Erfan Tasdighi Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, United States of AmericaSearch for more papers by this authorMichael J Blaha, Corresponding Author Michael J Blaha [email protected] Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, United States of America[email protected]Search for more papers by this author First published: 21 February 2023 https://doi.org/10.5694/mja2.51861Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011; 378: 684-692. 2Venkataraman P, Neil AL, Mitchell GK, et al. The cost-effectiveness of coronary calcium score-guided statin therapy initiation for Australians with family histories of premature coronary artery disease. Med J Aust 2023; 218: 216-222. 3Venkataraman P, Kawakami H, Huynh Q, et al. Cost-effectiveness of coronary artery calcium scoring in people with a family history of coronary disease. JACC Cardiovasc Imaging 2021; 14: 1206-1217. 4Hong JC, Blankstein R, Shaw LJ, et al. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis. JACC Cardiovasc Imaging 2017; 10: 938-952. 5Pletcher MJ, Pignone M, Earnshaw S, et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 2014; 7: 276-284. 6van Kempen BJH, Ferket BS, Steyerberg EW, et al. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population. Int J Cardiol 2016; 203: 422-431. 7van Kempen BJH, Spronk S, Koller MT, et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol 2011; 58: 1690-1701. 8Roberts ET, Horne A, Martin SS, et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One 2015; 10: e0116377. 9Galper BZ, Wang YC, Einstein AJ. Strategies for primary prevention of coronary heart disease based on risk stratification by the ACC/AHA lipid guidelines, ATP III guidelines, coronary calcium scoring, and C-reactive protein, and a global treat-all strategy: a comparative–effectiveness modeling study. PLoS One 2015; 10: e0138092. 10Sniderman AD, Thanassoulis G, Lawler PR, et al. Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk. Am J Cardiol 2012; 110: 530-533. 11Khan SS, Navar AM. The potential and pitfalls of coronary artery calcium scoring. JAMA Cardiol 2022; 7: 11-12. 12Søgaard R, Diederichsen ACP, Rasmussen LM, et al. Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish cardiovascular screening trial (DANCAVAS). Eur Heart J 2022; 43: 4392-4402. 13Al-Kindi SG, Costa M, Tashtish N, et al. No-charge coronary artery calcium screening for cardiovascular risk assessment. J Am Coll Cardiol 2020; 76: 1259-1262. Volume218, Issue5March 2023Pages 214-215 ReferencesRelatedInformation